» Articles » PMID: 23890060

The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures

Overview
Journal Immunity
Publisher Cell Press
Date 2013 Jul 30
PMID 23890060
Citations 466
Authors
Affiliations
Soon will be listed here.
Abstract

Numerous analyses of large patient cohorts identified specific patterns of immune activation associated with patient survival. We established these as the immune contexture, encompassing the type, functional orientation, density, and location of adaptive immune cells within distinct tumor regions. Based on the immune contexture, a standardized, powerful immune stratification system, the Immunoscore, was delineated. The immune contexture is characterized by immune signatures also observed in association with the broader phenomenon of immune-mediated, tissue-specific destruction. We defined these as the immunologic constant of rejection. Predictive, prognostic, and mechanistic immune signatures overlap, and a continuum of intratumor immune reactions exists. The balance between tumor cell growth and elimination may be tipped upon a crescendo induced by immune manipulations aimed at enhancing naturally occurring immunosurveillance. Here, we propose a broader immunological interpretation of these three concepts--immune contexture, Immunoscore, and immunologic constant of rejection--that segregates oncogenic processes independently of their tissue origin.

Citing Articles

Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols.

Cottrell T, Lotze M, Ali A, Bifulco C, Capitini C, Chow L J Immunother Cancer. 2025; 13(3).

PMID: 40054999 PMC: 11891540. DOI: 10.1136/jitc-2024-010928.


Advancement insights in cancer vaccines: mechanisms, types, and clinical applications.

Kamel G, Attia R, Al-Noman H, Salama L Mol Biol Rep. 2025; 52(1):290.

PMID: 40053260 DOI: 10.1007/s11033-025-10370-0.


Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review.

Cesano A, Augustin R, Barrea L, Bedognetti D, Bruno T, Carturan A J Immunother Cancer. 2025; 13(1).

PMID: 39824527 PMC: 11749597. DOI: 10.1136/jitc-2024-008876.


Tissue-resident memory T cells in diseases and therapeutic strategies.

Xie D, Lu G, Mai G, Guo Q, Xu G MedComm (2020). 2025; 6(1):e70053.

PMID: 39802636 PMC: 11725047. DOI: 10.1002/mco2.70053.


Tumor microenvironment and immunotherapy for triple-negative breast cancer.

Guo Z, Zhu Z, Lin X, Wang S, Wen Y, Wang L Biomark Res. 2024; 12(1):166.

PMID: 39741315 PMC: 11689763. DOI: 10.1186/s40364-024-00714-6.